Cysteinylated Albumin as a Potential Biomarker for the Progression of Kidney Disease in Patients With Type 2 Diabetes.

Saved in:
Bibliographic Details
Title: Cysteinylated Albumin as a Potential Biomarker for the Progression of Kidney Disease in Patients With Type 2 Diabetes.
Authors: Imafuku T; Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences, Kumamoto University, Kumamoto, Japan.; Lipid Metabolism Unit, Center for Computational and Integrative Biology, Massachusetts General Hospital, Boston, MA., Watanabe H; Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences, Kumamoto University, Kumamoto, Japan hnabe@kumamoto-u.ac.jp tomaru@gpo.kumamoto-u.ac.jp., Oniki K; Division of Pharmacology and Therapeutics, Graduate School of Pharmaceutical Sciences, Kumamoto University, Kumamoto, Japan., Yoshida A; Diabetes Care Center, Jinnouchi Hospital, Kumamoto, Japan., Kato H; Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences, Kumamoto University, Kumamoto, Japan., Nakano T; Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences, Kumamoto University, Kumamoto, Japan., Tokumaru K; Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences, Kumamoto University, Kumamoto, Japan., Fujita I; Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences, Kumamoto University, Kumamoto, Japan., Arimura N; Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences, Kumamoto University, Kumamoto, Japan., Maeda H; Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences, Kumamoto University, Kumamoto, Japan., Sakamoto Y; Division of Pharmacology and Therapeutics, Graduate School of Pharmaceutical Sciences, Kumamoto University, Kumamoto, Japan., Kondo N; Division of Pharmacology and Therapeutics, Graduate School of Pharmaceutical Sciences, Kumamoto University, Kumamoto, Japan., Morita A; Diabetes Care Center, Jinnouchi Hospital, Kumamoto, Japan., Saruwatari J; Division of Pharmacology and Therapeutics, Graduate School of Pharmaceutical Sciences, Kumamoto University, Kumamoto, Japan., Tanaka M; Department of Nephrology, Akebono Clinic, Kumamoto, Japan., Matsushita K; Department of Nephrology, Akebono Clinic, Kumamoto, Japan., Wada T; Department of Nephrology and Laboratory Medicine, Faculty of Medicine, Institute of Medical, Pharmaceutical and Health Sciences, Graduate School of Medical Sciences, Kanazawa University, Kanazawa, Japan., Fukagawa M; Division of Nephrology, Endocrinology and Metabolism, Tokai University School of Medicine, Kanagawa, Japan., Otagiri M; Faculty of Pharmaceutical Sciences, Sojo University, Kumamoto, Japan., Fitzgerald ML; Lipid Metabolism Unit, Center for Computational and Integrative Biology, Massachusetts General Hospital, Boston, MA., Jinnouchi H; Diabetes Care Center, Jinnouchi Hospital, Kumamoto, Japan., Maruyama T; Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences, Kumamoto University, Kumamoto, Japan hnabe@kumamoto-u.ac.jp tomaru@gpo.kumamoto-u.ac.jp.
Source: Diabetes care [Diabetes Care] 2021 Jun; Vol. 44 (6), pp. e115-e117. Date of Electronic Publication: 2021 Apr 26.
Publication Type: Letter; Research Support, Non-U.S. Gov't
Journal Info: Publisher: American Diabetes Association Country of Publication: United States NLM ID: 7805975 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1935-5548 (Electronic) Linking ISSN: 01495992 NLM ISO Abbreviation: Diabetes Care Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1935-5548
DOI:10.2337/dc20-3003